ProMIS Neurosciences PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing antibody therapies and therapeutic vaccines for neurodegenerative diseases driven by misfolded proteins. The company leverages its proprietary EpiSelect™ computational platform to identify disease-specific epitopes on toxic misfolded proteins such as amyloid-beta in Alzheimer’s disease, TDP-43 in ALS, and alpha-synuclein in Parkinson’s disease and related synucleinopathies. ProMIS aims to create highly selective therapeutics that target pathogenic protein forms without disrupting normal protein function, offering a precision medicine approach to complex neurological disorders.

ProMIS generates revenue primarily through research funding, licensing agreements, milestone payments, and potential royalties from collaborations with pharmaceutical partners. The company has not yet generated significant product revenues as its candidates remain in preclinical and clinical development stages. Revenue expectations are tied to future out-licensing deals, co-development funding, and successful advancement of its pipeline candidates through clinical trials toward potential commercialization by strategic partners.

The company operates through the following segments:

• Alzheimer’s Disease Program: This segment focuses on the development of PMN310, a monoclonal antibody designed to selectively target toxic soluble oligomers of amyloid-beta without binding to monomers or plaque. PMN310 is being evaluated in the PRECISE-AD Phase 1b trial for early Alzheimer’s disease, with top-line data anticipated in early 2027. The program also includes an Alzheimer’s vaccine initiative using conformational epitopes linked to carrier proteins to induce selective antibody responses without harmful T-cell activation.

• Amyotrophic Lateral Sclerosis Program: This segment includes PMN267, a humanized monoclonal antibody targeting misfolded TDP-43 cytoplasmic aggregates, and intrabody versions designed to degrade intracellular TDP-43 pathology. Preclinical studies show PMN267 inhibits cell-to-cell transmission of misfolded TDP-43 and reduces stress-induced aggregates in ALS patient-derived motor neurons. The segment also explores RACK1 as an additional ALS target, with selective antibodies generated against misfolded RACK1 using the ProMIS discovery platform.

• Synucleinopathies Program: This segment centers on PMN442, a monoclonal antibody that selectively binds toxic oligomers and soluble fibrils of alpha-synuclein while sparing monomers and physiologic tetramers. PMN442 has demonstrated protection of dopaminergic neurons and inhibition of alpha-synuclein seeding activity in preclinical models. The program supports development for Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, with vaccine candidates also under investigation using similar epitope-based approaches.

ProMIS holds a differentiated position in the neurodegenerative disease therapeutics space due to its epitope-specific targeting technology, which enables selectivity for toxic protein conformers over normal forms—a feature not consistently achieved by competing antibodies. While companies like Biogen, Eisai, and Lilly have approved anti-amyloid therapies (Aduhelm, Leqembi, Kisunla) that bind both oligomers and plaques, ProMIS’ PMN310 aims to avoid plaque binding to reduce ARIA risk and improve therapeutic index. In ALS and synucleinopathies, few disease-modifying approaches exist, giving ProMIS’ TDP-43 and alpha-synuclein programs a first-mover advantage in precision targeting, though competition includes academic and biotech efforts targeting similar pathways.

ProMIS serves patients suffering from neurodegenerative diseases including Alzheimer’s disease, ALS, Parkinson’s disease, and related dementias, as well as individuals at genetic or biomarker-defined risk for these conditions. The company’s therapeutic and vaccine candidates are intended for use in clinical settings under physician supervision, with potential distribution through hospitals, infusion centers, and specialty neurology clinics upon regulatory approval and commercialization via partner networks.